Skip to main content

Table 2 Demographic and lymphedema stages of cases and control

From: Association between the single-nucleotide polymorphism (rs1030868) variant in matrix metallopeptidase 2 gene and the development of lymphedema

Variable

Stage I (1)

(n = 5)

Stage II (2)

(n = 13)

Stage III (3)

(n = 10)

Stage IV (4)

(n = 25)

Stage V (5)

(n = 13)

Stage VI (6)

(n = 19)

Stage VII (7)

(n = 8)

P value

Age/years

62.40 ± 3.6

58.85 ± 6.1

56.70 ± 7.3

41.56 ± 14.6

47.08 ± 9.8

46.01 ± 13.2

53.01 ± 6.1

< 0.001*

P value**

1 vs. 2 = 0.353

2 vs. 3 = 0.976

3 vs. 4 = 0.001

4 vs. 5 = 0.157

5 vs. 6 = 0.792

6 vs. 7 = 0.145

1 vs. 7 = 0.148

1 vs. 3 = 0.360

2 vs. 4 < 0.001

3 vs. 5 = 0.046

4 vs. 6 = 0.200

5 vs. 7 = 0.247

1 vs. 6 = 0.005

2 vs. 7 = 0.451

1 vs. 4 < 0.001

2 vs. 5 = 0.030

3 vs. 6 = 0.017

4 vs. 7 = 0.015

1 vs. 5 = 0.012

2 vs. 6 = 0.009

3 vs. 7 = 0.492

Sex

 Female

5 (100%)

7 (53.8%)

5 (50%)

15 (60%)

5 (38.5%)

16 (84.2%)

4 (50%)

= 0.033***

 Male

0 (0%)

6 (46.2%)

5 (50%)

10 (40%)

8 (61.5%)

3 (15.8%)

4 (50%)

 
  1. Bold values denote statistical significance at the P < 0.05 level
  2. *One-way ANOVA test was used to compare means between groups
  3. **Post hoc test was used for Pairwise Comparisons
  4. ***Chi-square test was used to compare the frequency distribution